Needham Downgrades Theseus Pharmaceuticals to Hold
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia has downgraded Theseus Pharmaceuticals (NASDAQ:THRX) from Buy to Hold.

July 14, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Theseus Pharmaceuticals has been downgraded from Buy to Hold by Needham analyst Ami Fadia.
The downgrade from Buy to Hold by a Needham analyst indicates a less optimistic outlook for the company's stock in the short term. This could potentially lead to a decrease in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100